New drug PIT565 tested in blood cancer patients who failed prior therapies
NCT ID NCT05397496
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug called PIT565 in about 61 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. The main goal is to check the drug's safety and find the best dose. Participants must have tried at least two prior treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA (B-NHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Créteil, 94010, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Reggio Emilia, RE, 42123, Italy
-
Novartis Investigative Site
Kashiwa, Chiba, 277-8577, Japan
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
The University of Kansas Clinical Research Ctr
Fairway, Kansas, 66205, United States
-
University Of Miami
Miami, Florida, 33136, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.